Q3 2021 Endo International plc Earnings Conference Call

Q3 2021 Earnings Report

endo.com

©2021 Endo International plc or one of its affiliates. All rights reserved

Forward Looking Statements; Non-GAAP Financial Measures

This presentation contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1 995 and Canadian securities legislation.

Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "look forward," "intend," "guidance," "future projects" or

similar expressions are forward looking statements. Because these statements reflect our current views, expectations and beli efs concerning future events, these forward looking statements involve risks and uncertainties. Although Endo believes that these forward looking statements and informat ion are based upon reasonable assumptions and expectations, readers should not place undue reliance on them, or any other forward looking statements or inf ormation in this news release. Investors should note that many factors, as more fully described in the documents filed by Endo with securities regulators in the Unite d States and Canada including under the caption "Risk Factors" in Endo's Form 10-K, Form 10-Q and Form 8-K filings, as applicable, with the Securities and Exchange Commission and with securities regulators in Canada on System for Electronic Document Analysis and Retrieval ("SEDAR") and as otherwise enumerated herein or therein, c ould affect Endo's future financial results and could cause Endo's actual results to differ materially from those expressed in any forward looking statements. Th e forward looking statements in this presentation are qualified by these risk factors. Endo assumes no obligation to publicly update any forward looking statement s, whether as a result of new information, future developments or otherwise, except as may be required under applicable securities law.

This presentation may refer to non-GAAP financial measures, including, among others, adjusted diluted net income per share from continuing operations, adjusted EBITDA, adjusted income from continuing operations, adjusted gross margin, adjusted operating expenses, adjusted effective ta x rate, adjusted revenue and adjusted weighted average diluted shares that are not prepared in accordance with accounting principles generally accepted in the Unit ed States and that may be different from non-GAAP financial measures used by other companies. Endo utilizes these financial measures because (i) they are used by Endo, along with financial measures in

accordance with GAAP, to evaluate Endo's operating performance; (ii) Endo believes that they will be used by certain investor s to measure Endo's operating results; (iii) the Compensation & Human Capital Committee of Endo's Board of Directors uses adjusted diluted net income per share from continuing operations and adjusted EBITDA, or measures derived from such, in assessing the performance and compensation of substantially all of Endo's employees , including executive officers and (iv) Endo's leverage ratio, as defined by Endo's credit agreement, is calculated based on non -GAAP financial measures. Endo believes that presenting these non-GAAP measures provides useful information about Endo's performance across reporting periods on a consistent basis by excluding cer tain items, which may be favorable or unfavorable, pursuant to certain specified procedures. These non-GAAP measures should be considered supplemental to and not a substitute for financial information prepared in accordance with GAAP. Endo's definition of these non-GAAP measures may differ from similarly titled measures used by others. Investors are encouraged to review Endo's current report on Form 8-K furnished to the SEC on Nov 4, 2021, including exhibit 99.1 thereto, for Endo's definition of the non-GAAP financial measures

in this presentation as well as a reconciliation of these non-GAAP financial measures to the most directly comparable GAAP measures.

1	©2021 Endo International plc or one of its affiliates. All rights reserved

Today's Agenda

• Strategic Priorities
• Business Performance
• Pipeline Update
• Financial Results & Guidance
• Q&A

2	©2021 Endo International plc or one of its affiliates. All rights reserved

Our Strategic Priorities

Expand &

Enhance Our

Portfolio

We are investing to build a more differentiated and durable portfolio that

benefits our customers and creates sustainable long- term value.

Reinvent How We Work

We are embracing the future by accelerating new ways of working to

better serve our customers, promote innovation, and improve productivity.

Be A Force

For Good

We are committed to the adoption of more sustainable practices

that positively impact our stakeholders, including the promotion of diversity & inclusion in all we do.

3	©2021 Endo International plc or one of its affiliates. All rights reserved

Q3 2021 Snapshot

Revenues (U.S. $M)	Q3 2021	Q3 2020
Branded Pharmaceuticals	$231	$224
Sterile Injectables	$344	$251
Generic Pharmaceuticals	$174	$136
International Pharmaceuticals	$ 23	$ 24
Total Revenues	$772	$635
Adjusted EBITDA	$387	$287

Table may not total due to rounding

4	©2021 Endo International plc or one of its affiliates. All rights reserved